These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 16300476)
21. Expression, intracellular distribution and basis for lack of catalytic activity of the PDE4A7 isoform encoded by the human PDE4A cAMP-specific phosphodiesterase gene. Johnston LA; Erdogan S; Cheung YF; Sullivan M; Barber R; Lynch MJ; Baillie GS; Van Heeke G; Adams DR; Huston E; Houslay MD Biochem J; 2004 Jun; 380(Pt 2):371-84. PubMed ID: 15025561 [TBL] [Abstract][Full Text] [Related]
22. The potential of phosphodiesterase 4 inhibitors for the treatment of depression: opportunities and challenges. Renau TE Curr Opin Investig Drugs; 2004 Jan; 5(1):34-9. PubMed ID: 14983971 [TBL] [Abstract][Full Text] [Related]
23. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors. Kelly JJ; Barnes PJ; Giembycz MA Br J Pharmacol; 1998 May; 124(1):129-40. PubMed ID: 9630352 [TBL] [Abstract][Full Text] [Related]
24. Implications of PDE4 structure on inhibitor selectivity across PDE families. Ke H Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132 [TBL] [Abstract][Full Text] [Related]
25. Dissecting the cofactor-dependent and independent bindings of PDE4 inhibitors. Liu S; Laliberté F; Bobechko B; Bartlett A; Lario P; Gorseth E; Van Hamme J; Gresser MJ; Huang Z Biochemistry; 2001 Aug; 40(34):10179-86. PubMed ID: 11513595 [TBL] [Abstract][Full Text] [Related]
26. Effects of the novel PDE4 inhibitors MEM1018 and MEM1091 on memory in the radial-arm maze and inhibitory avoidance tests in rats. Zhang HT; Huang Y; Suvarna NU; Deng C; Crissman AM; Hopper AT; De Vivo M; Rose GM; O'Donnell JM Psychopharmacology (Berl); 2005 May; 179(3):613-9. PubMed ID: 15672274 [TBL] [Abstract][Full Text] [Related]
27. Crystal structure of phosphodiesterase 4D and inhibitor complex(1). Lee ME; Markowitz J; Lee JO; Lee H FEBS Lett; 2002 Oct; 530(1-3):53-8. PubMed ID: 12387865 [TBL] [Abstract][Full Text] [Related]
28. Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity. Huai Q; Wang H; Sun Y; Kim HY; Liu Y; Ke H Structure; 2003 Jul; 11(7):865-73. PubMed ID: 12842049 [TBL] [Abstract][Full Text] [Related]
29. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma. Deng YM; Xie QM; Tang HF; Sun JG; Deng JF; Chen JQ; Yang SY Eur J Pharmacol; 2006 Oct; 547(1-3):125-35. PubMed ID: 16956605 [TBL] [Abstract][Full Text] [Related]
30. Evidence for a role of phosphodiesterase 4 in lipopolysaccharide-stimulated prostaglandin E2 production and matrix metalloproteinase-9 activity in human amniochorionic membranes. Oger S; Méhats C; Dallot E; Cabrol D; Leroy MJ J Immunol; 2005 Jun; 174(12):8082-9. PubMed ID: 15944316 [TBL] [Abstract][Full Text] [Related]
31. Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram. Michie AM; Lobban M; Müller T; Harnett MM; Houslay MD Cell Signal; 1996 Feb; 8(2):97-110. PubMed ID: 8730511 [TBL] [Abstract][Full Text] [Related]
32. New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease. Barnette MS; Underwood DC Curr Opin Pulm Med; 2000 Mar; 6(2):164-9. PubMed ID: 10741778 [TBL] [Abstract][Full Text] [Related]
33. Highly potent PDE4 inhibitors with therapeutic potential. Ochiai H; Ohtani T; Ishida A; Kusumi K; Kato M; Kohno H; Kishikawa K; Obata T; Nakai H; Toda M Bioorg Med Chem Lett; 2004 Jan; 14(1):207-10. PubMed ID: 14684329 [TBL] [Abstract][Full Text] [Related]
34. Update on the therapeutic potential of PDE4 inhibitors. Dyke HJ; Montana JG Expert Opin Investig Drugs; 2002 Jan; 11(1):1-13. PubMed ID: 11772317 [TBL] [Abstract][Full Text] [Related]
35. PDE4B5, a novel, super-short, brain-specific cAMP phosphodiesterase-4 variant whose isoform-specifying N-terminal region is identical to that of cAMP phosphodiesterase-4D6 (PDE4D6). Cheung YF; Kan Z; Garrett-Engele P; Gall I; Murdoch H; Baillie GS; Camargo LM; Johnson JM; Houslay MD; Castle JC J Pharmacol Exp Ther; 2007 Aug; 322(2):600-9. PubMed ID: 17519386 [TBL] [Abstract][Full Text] [Related]
39. Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ current in rat ventricular myocytes. Verde I; Vandecasteele G; Lezoualc'h F; Fischmeister R Br J Pharmacol; 1999 May; 127(1):65-74. PubMed ID: 10369457 [TBL] [Abstract][Full Text] [Related]
40. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Dastidar SG; Rajagopal D; Ray A Curr Opin Investig Drugs; 2007 May; 8(5):364-72. PubMed ID: 17520865 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]